| CL1991B |
|
2805804-54-8 |
CP-547632 TFA
CP-547632 TFA
-
98+%
|
需詢價(jià) |
C20H24BrF2N5O3S·C2HF3O2 |
|
|
|
| CL2879A |
|
210644-62-5 |
(Z)-奧蘭替尼 | (Z)-SU6668 | (Z)-TSU-68
(Z)-Orantinib | (Z)-SU6668 | (Z)-TSU-68
-
98+%
|
需詢價(jià) |
C18H18N2O3 |
|
|
|
| CL2509 |
|
1013920-15-4 |
伏羅尼布
Vorolanib (X-82,CM082)
3-5days
98+%
|
￥850.00 |
C23H26FN5O3 |
|
|
|
| CL2424 |
|
557795-19-4 |
舒尼替尼 | 舒尼替尼堿
Sunitinib | Sunitinib Base
In-stock
99+%
|
￥466.00 |
C22H27FN4O2 |
|
|
|
| CLA1508 |
|
1607793-29-2 |
法瑞西單抗
Anti-Human VEGFAxANGPT2 (Faricimab; RG7716)
-
95+%
|
需詢價(jià) |
— |
|
|
|
| CLA1500 |
|
1969309-56-5 |
澤妥珠單抗
Anti-Human Her2xHer3 (Zenocutuzumab; MCLA-128; PB4188; R040517)
-
95+%
|
需詢價(jià) |
— |
|
|
|
| CLA1339 |
|
1350624-75-7 |
瑪格妥昔單抗
Margetuximab (Anti-ERBB2 / HER2 / CD340)
3-5days
95+%
|
￥3600.00 |
— |
|
|
|
| CLA1267 |
|
1024603-92-6 |
艾蘆庫單抗
Icrucumab (Anti-VEGFR1 / FLT1)
3-5days
95+%
|
￥2500.00 |
— |
|
|
|
| CLA1179 |
|
934216-54-3 |
阿拉賽珠單抗
Alacizumab (Anti-VEGFR2 / KDR / CD309)
3-5days
95+%
|
￥4000.00 |
— |
|
|
|
| CL2214 |
|
215543-92-3 |
SU 5402 | SU-5402
(Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid.
In-stock
98+%
|
￥550.00 |
C17H16N2O3 |
|
|
|
| CLA1033 |
|
1018448-65-1 |
曲妥珠單抗-美坦新偶聯(lián)物 (TDM-1)
Ado-trastuzumab Emtansine (TDM-1)
3-5days
95+%
|
￥5200.00 |
— |
|
|
|
| CL1631 |
|
288383-20-0 |
西地尼布
Cediranib | ADZ-2171 | NSC-732208
-
98+%
|
需詢價(jià) |
C25H27FN4O3 |
|
|
|
| CL1633 |
|
417716-92-8 |
樂伐替尼 | 侖伐替尼 | 樂法替尼 | E7080
Lenvatinib | E7080
-
98+%
|
需詢價(jià) |
C21H19ClN4O4 |
|
|
|
| CL1636 |
|
444731-52-6 |
帕唑帕尼
Pazopanib | GW786034
-
99+%
|
需詢價(jià) |
C21H23N7O2S |
|
|
|
| CL1637 |
|
319460-85-0 |
阿西替尼 | 阿昔替尼
Axitinib | AG-013736
In-stock
98+%
|
￥588.00 |
C22H18N4OS |
|
|
|
| CL1033 |
|
808118-40-3 |
羅沙司他
Roxadustat | FG-4592
-
98+%
|
需詢價(jià) |
C19H16N2O5 |
|
|
|
| CLA1025 |
|
380610-27-5 |
帕妥珠單抗
Pertuzumab; 2C4
3-5days
98+%
|
￥2000.00 |
— |
|
|
|
| CLA1018 |
|
947687-13-0 |
雷莫蘆單抗
Ramucirumab; LY3009806; IMC-1121B
3-5days
98+%
|
￥2000.00 |
— |
|
|
|
| CLA1008 |
|
216974-75-3 |
貝伐單抗
Bevacizumab (anti-VEGF) | RhuMab VEGF
3-5days
95+%
|
￥1500.00 |
— |
|
|
|
| CL1991 |
|
252003-65-9 |
3-((4-溴-2,6-二氟芐基)氧基)-5-(3-(4-(吡咯烷-1-基)丁基)脲基)異噻唑-4-甲酰胺
CP-547632 | PAN-90806 | CP-632 | OSI-632
3-5days
98+%
|
￥366.00 |
C20H24BrF2N5O3S |
|
|
|
